Table 2.

Clinical studies on adjuvant therapy using pyrotinib

No.	Registration ID	Title	Target sample size	Outcomes
1	ChiCTR2200058746	Multicenter cohort study on efficacy and safety of HER2-positive, node-positive breast cancer following intensive adjuvant or neoadjuvant anti-HER2 therapy with pyrotinib	200	iDFS, DDFS, OS
2	ChiCTR2100049018	A randomized, open-label, multicenter study to evaluate the efficacy and safety of continuation of original targeted therapy versus Trastuzumab combined with Pyrotinib and capecitabine as postoperative adjuvant therapy in patients with HER2-positive early breast cancer who have residual tumor present pathologically following	206	3-year iDFS rate
3	ChiCTR2000040866	Comparison of Pyrotinib or Pertuzumab Combined with Trastuzumab for non-pCR HER2 Positive Breast Cancer after Neoadjuvant Therapy: A Randomized, Open, Prospective Clinical Study	546	iDFS, DFS, OS, BCSS, safty
4	ChiCTR2000038503	Pyrotinib and Trastuzumab for Early or Local Advanced HER2-Positive Breast Cancer	97	iDFS, OS, DFS, DDFS, safty
5	NCT04254263	Adjuvant Study of Pyrotinib in HER2 Positive Breast Cancer (ATP)	316	iDFS, DFS, OS
6	NCT04659499	Nab-paclitaxel in Combination with Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer	261	3-year DFS, AEs + SAEs
7	NCT03980054	A Study of Evaluating the Effects of Pyrotinib After Adjuvant Trastuzumab in Women with Early stage Breast Cancer	1192	iDFS, DFS, OS, DDFS
8	NCT05292742	Compare Continuation of Original Targeted Therapy with Trastuzumab Combined with Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients with HER2 Positive Early Breast Cancer	206	iDFS

iDFS invasive disease-free survival; DDFS distant disease-free survival; OS overall survival; DFS disease-free survival; BCSS breast cancer-specific survival; AEs adverse events; SAEs severe adverse events